Back to News
Market Impact: 0.3
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat
Source: 247wallst.com
Analyst InsightsHealthcare & BiotechCompany Fundamentals
Citigroup downgraded Moderna to Sell from Hold, arguing that the stock's recent rally has lifted its valuation materially beyond what the biotech company's pipeline can reasonably support. The downgrade creates a near-term bearish catalyst for MRNA and highlights investor risk around pipeline-driven valuation assumptions.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
C0.05
MRNA-0.75
More News
- Why is Nidec stock plunging today?
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Moderna has been on a tear since mid-August. Citi now sees it plunging 60%
- Why is Moderna stock down 4% today?
- Warner Bros Discovery stock hits 52-week high at $30.93
- Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year